ELVN
Enliven Therapeutics, Inc.
$37.32
-2.01
(-5.11%)
Mkt Cap
2.73B
Volume
1,188,421
52W Range
14.785-62.32
Sector
Healthcare
Beta
0.24
EPS (TTM)
-1.64 USD
P/E Ratio
-8.42
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (103.69M) | (89.02M) | (71.58M) | (37.66M) | (24.74M) | (18.97M) | (23.46M) | (11.34M) | 0 |
| EPS | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 | -5.43 | -2.62 | 0.00 |
| Free Cash Flow | (70.46M) | (73.24M) | (61.42M) | (32.69M) | (19.32M) | (8.99M) | (22.02M) | (8.78M) | (8.79M) |
| FCF / Share | -1.24 | -1.56 | -1.73 | -5.23 | -2.47 | -2.05 | -5.10 | -2.03 | -2.03 |
| Operating CF | (70.30M) | (73.19M) | (61.27M) | (32.08M) | (19.13M) | (8.53M) | (21.88M) | (8.78M) | (8.79M) |
| Total Assets | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M | 90.84M | 33.30M | 7.71M | 10.22M |
| Total Debt | 399,000 | 0 | 335,000 | 323,000 | 159,000 | 0 | 0 | 0 | 660,000 |
| Cash & Equiv | 98.90M | 124.12M | 100.14M | 75.54M | 110.02M | 47.70M | 4.94M | 7.38M | 9.67M |
| Book Value | 459.60M | 309.85M | 245.91M | (76.83M) | 106.86M | 84.44M | (48.85M) | (26.32M) | (15.53M) |
| Return on Equity | -0.23 | -0.29 | -0.29 | N/A | -0.23 | -0.22 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.48M) | (23.63M) | (29.67M) | (20.15M) | (25.34M) | (28.54M) | (23.18M) | (23.16M) | (19.95M) | (22.74M) | (19.37M) | (20.77M) |
| EPS | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 |
| Free Cash Flow | (18.63M) | (19.29M) | (15.84M) | (13.28M) | (17.20M) | (24.15M) | (17.20M) | (12.21M) | (20.44M) | (23.38M) | (12.50M) | (15.91M) |
| FCF / Share | -0.28 | -0.31 | -0.28 | -0.21 | -0.33 | -0.48 | -0.35 | -0.25 | -0.43 | -0.56 | -0.30 | -0.39 |
| Operating CF | (18.53M) | (19.29M) | (15.84M) | (13.28M) | (17.06M) | (24.13M) | (17.20M) | (12.19M) | (20.43M) | (23.36M) | (12.48M) | (15.89M) |
| Total Assets | 910.22M | 464.85M | 476.17M | 490.88M | 503.89M | 302.57M | 325.76M | 305.43M | 327.04M | 342.78M | 271.87M | 274.04M |
| Total Debt | 1.51M | 302,000 | 399,000 | 387,000 | 580,000 | 365,000 | 0 | 85,000 | 169,000 | 252,000 | 335,000 | 332,000 |
| Cash & Equiv | 135.50M | 132.18M | 98.90M | 101.73M | 119.44M | 101.70M | 124.12M | 100.62M | 96.87M | 149.16M | 100.14M | 73.85M |
| Book Value | 895.15M | 453.37M | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M | 245.91M | 261.75M |
| Return on Equity | -0.04 | -0.05 | -0.06 | -0.04 | -0.05 | -0.10 | -0.07 | -0.08 | -0.07 | -0.07 | -0.08 | -0.08 |
ELVN News
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says